stella
beta
High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI — Stella
Recruiting
Back to Non-Small Cell Lung Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Fudan university shanghai cancer center, Shanghai, Shanghai Municipality
View full record on ClinicalTrials.gov